Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients
- Sponsor
- Istinye University
- Study ID
- NCT07332715
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Acute Kidney Injury
- Sepsis-Related Mortality
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Non-interventional / Observational Study — OTHERThis is a non-interventional, observational study. No diagnostic or therapeutic intervention will be applied beyond routine clinical care. Blood uric acid, albumin, and serum lactate levels measured as part of standard intensive care management will be recorded at admission, and lactate levels will be reassessed at 24 hours. Patients will be followed prospectively during their intensive care stay to evaluate the development of acute kidney injury, vasopressor requirement, and 28-day mortality.
Study Details
Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection and remains a leading cause of morbidity and mortality in intensive care units. Early identification of patients at high risk for adverse outcomes is essential for timely intervention and improved prognosis. This prospective, single-center, non-interventional study aims to evaluate the predictive value of the combined use of the blood uric acid/albumin ratio (UAR) and serum lactate levels in patients aged 65 years and older who are admitted to the intensive care unit with a diagnosis of sepsis according to SEPSIS-3 criteria. Patients without acute kidney injury at admission and with at least 24 hours of intensive care follow-up will be included. The primary outcome is the development of acute kidney injury within the first 7 days of ICU admission according to KDIGO criteria. Secondary outcomes include vasopressor requirement during ICU stay, changes in serum lactate levels over the first 24 hours, and 28-day mortality. The study seeks to determine whether the combination of UAR and lactate levels can serve as an easily accessible and clinically applicable biomarker to predict adverse outcomes and support prognostic assessment and treatment strategies in sepsis patients.
Key Dates
- First listed
- Jan 12, 2026
- Start date
- Jan 15, 2026
- Status verified
- Jan 2026
- Primary completion
- May 15, 2026
- Completion
- May 31, 2026
Study Design
- Enrollment
- 80 participants (estimated)
Primary Outcome Measure
Development of Acute Kidney Injury (AKI) [ Time Frame: Within the first 7 days following intensive care unit admission ]
Central Contacts
- İLKE DOLĞUN+905555485632
Related Studies
- Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric AKIEnrolling By Invitation · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
- The Biosonographic IndexRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Biorepository to Support Research in Kidney DiseasesEnrolling By Invitation · Yale University · New Haven, Connecticut
- A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health InterventionRecruiting · Duke University · Durham, North Carolina